FDA rejects Byetta data

Nov. 6, 2008 at 12:04 AM

WASHINGTON, Nov. 6 (UPI) -- The U.S. Food and Drug Administration has rejected research data for a long-acting version of the diabetes drug Byetta.

The FDA rejected Eli Lilly's studies comparing small-scale batches of Byetta LAR made by partner Alkermes to large-scale batches made at an Amylin Pharmaceuticals manufacturing plant, Amylin said. Conducting a new study could delay the company's plans to seek approval next year, the Indianapolis Star reported.

The version of Byetta currently on the market is a twice-a-day injectable drug to help diabetics control their blood sugar, the newspaper said.

Related UPI Stories
Latest Headlines
Trending News
Sex causes immune response to increase chance of pregnancy
Ancient rocks reveal earliest instance of photosynthesis
Smoking cessation drug effective for women faster than men
Gene therapy effective against form of inherited vision loss
NASA releases thousands of Apollo mission photos on Flickr